Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 542

1.

Persistence with hepatitis C therapy in the Department of Veterans Affairs.

Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L.

J Clin Pharm Ther. 2008 Jun;33(3):251-61. doi: 10.1111/j.1365-2710.2008.00912.x.

PMID:
18452412
[PubMed - indexed for MEDLINE]
2.

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.

Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

J Interferon Cytokine Res. 2008 Oct;28(10):623-9. doi: 10.1089/jir.2007.0116.

PMID:
18778199
[PubMed - indexed for MEDLINE]
3.

Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.

Sporea I, Danila M, Sirli R, Popescu A, Laza A, Baditoiu L.

J Gastrointestin Liver Dis. 2006 Jun;15(2):125-30.

PMID:
16802006
[PubMed - indexed for MEDLINE]
Free Article
4.

Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.

Zopf S, Herold C, Hahn EG, Ganslmayer M.

Scand J Gastroenterol. 2009;44(4):486-90. doi: 10.1080/00365520802647400.

PMID:
19117241
[PubMed - indexed for MEDLINE]
5.

Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.

Toyoda H, Kumada T.

Expert Opin Pharmacother. 2009 Dec;10(17):2845-57. doi: 10.1517/14656560903321521. Review.

PMID:
19891593
[PubMed - indexed for MEDLINE]
6.
7.

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.

Brixner DI, Ye X, Chu TC, Blumentals WA, Hassanein TI.

Am J Health Syst Pharm. 2009 Dec 15;66(24):2171-8. doi: 10.2146/ajhp080711.

PMID:
19966085
[PubMed - indexed for MEDLINE]
8.

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

McHutchison J, Sulkowski M.

J Viral Hepat. 2008 Jul;15(7):475-81. doi: 10.1111/j.1365-2893.2008.00973.x. Epub 2008 Mar 24.

PMID:
18363672
[PubMed - indexed for MEDLINE]
9.

[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].

Lee HJ, Eun JR, Choi JW, Kim KO, Moon HJ.

Korean J Hepatol. 2008 Mar;14(1):46-57. doi: 10.3350/kjhep.2008.14.1.46. Korean.

PMID:
18367857
[PubMed - indexed for MEDLINE]
Free Article
10.

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.

Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.

Liver Int. 2007 Sep;27(7):954-9.

PMID:
17696934
[PubMed - indexed for MEDLINE]
11.

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.

Katano Y, Kumada T, Nakano I, Toyoda H, Ishigami M, Hayashi K, Honda T, Goto H.

Hepatogastroenterology. 2009 Mar-Apr;56(90):485-91.

PMID:
19579626
[PubMed - indexed for MEDLINE]
12.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
13.

[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].

Márquez Peiró JF, Valero Alcocer VE, Morales Suárez-Varela M, Llopis González A, Pérez Peiró C.

Med Clin (Barc). 2007 Nov 3;129(16):612-4. Spanish.

PMID:
18001672
[PubMed - indexed for MEDLINE]
14.

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A.

Dig Dis Sci. 2011 Aug;56(8):2439-48. doi: 10.1007/s10620-011-1746-3. Epub 2011 Jun 2.

PMID:
21633833
[PubMed - indexed for MEDLINE]
15.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
[PubMed - indexed for MEDLINE]
16.

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.

Foster GR.

Expert Opin Pharmacother. 2003 May;4(5):685-91. Review.

PMID:
12739994
[PubMed - indexed for MEDLINE]
17.

PEG-interferon in acute and chronic hepatitis C: a review.

Palumbo E.

Am J Ther. 2009 Nov-Dec;16(6):573-8. doi: 10.1097/MJT.0b013e3181960819. Review.

PMID:
19433975
[PubMed - indexed for MEDLINE]
18.

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1256-63. doi: 10.1093/jac/dkp106. Epub 2009 Apr 10.

PMID:
19363085
[PubMed - indexed for MEDLINE]
Free Article
19.

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.

Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, Hu S, Klaskala W.

J Viral Hepat. 2004 Mar;11(2):157-65.

PMID:
14996351
[PubMed - indexed for MEDLINE]
20.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk